Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 11/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6386168 | 1.00 | ITGB3 (0.55) | ITGB3ITGA2BHDAC1HDAC4CTSK | |
| SCHEMBL6390296 | 0.93 | ITGB3 (0.55) | ITGB3ITGA2BHDAC1HDAC4CTSK | |
| SCHEMBL6392307 | 0.93 | ITGB3 (0.55) | ITGB3ITGA2BHDAC1HDAC4CTSK | |
| SCHEMBL6389169 | 0.86 | ITGB3 (0.54) | ITGB3ITGA2BHDAC1HDAC4CTSK | |
| SCHEMBL4906241 | 0.86 | ITGB3 (0.54) | ITGB3ITGA2BHDAC1HDAC4CTSK | |
| SCHEMBL6384973 | 0.84 | ITGB3 (0.58) | ITGB3ITGA2BHDAC1HDAC4CTSK | |
| SCHEMBL6384976 | 0.84 | ITGB3 (0.58) | ITGB3ITGA2BHDAC1HDAC4CTSK | |
| SCHEMBL7964692 | 0.84 | ITGB3 (0.66) | ITGB3ITGA2BHDAC1HDAC4CTSK | |
| SCHEMBL6768135 | 0.84 | ITGB3 (0.66) | ITGB3ITGA2BHDAC1HDAC4CTSK | |
| SCHEMBL6386611 | 0.83 | ITGB3 (0.42) | ITGB3ITGA2BHDAC1HDAC4CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005019168-A2 | FLUORINATED LYSINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050043292-A1 | Fluorinated lysine derivatives as dipeptidyl peptidase IV inhibitors | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043292-A1 | Fluorinated lysine derivatives as dipeptidyl peptidase IV inhibitors | DPP4, DPP7, ALPI | ITGB3 335/4885ITGA2B 660/4885HDAC1 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.